Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H17NO4.ClH |
Molecular Weight | 239.697 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(=O)OC(CC([O-])=O)C[N+](C)(C)C
InChI
InChIKey=JATPLOXBFFRHDN-UHFFFAOYSA-N
InChI=1S/C9H17NO4.ClH/c1-7(11)14-8(5-9(12)13)6-10(2,3)4;/h8H,5-6H2,1-4H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C9H17NO4 |
Molecular Weight | 203.2356 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
L-acetylcarnitine or acet-L-carnitine, a compound, naturally produced by the body, is necessary for fatty-acid metabolism and energy production. It is often taken as a dietary supplement. The mechanisms of action of acetylcarnitine have not been fully elucidated, but it seems that the main role of acetylcarnitine is to donate an acetyl group during fatty acid metabolism to help transport fatty acids, such as acetyl CoA, into the mitochondrial matrix where fatty acid metabolism occurs. L-acetylcarnitine is an investigational drug, which is approved in some countries, for example in Italy for diabetic neuropathy. Phase IV of clinical trials have revealed, that it also effective agent to treat the Alzheimer's disease. In contrary, the efficacy of L-acetylcarnitine as a prophylaxis in migraine patients did not provide evidence of benefit for efficacy. Besides, Acetyl-L-carnitine was in clinical trial Phase III to investigate its efficacy in the treatment of peripheral sensory neuropathy that anti-cancer chemotherapeutics induce. Recently published article unexpectedly discovered that this drug increased chemotherapy-induced peripheral neuropathy in a randomized trial.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2073722 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12089149 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Long-term acetyl-L-carnitine treatment in Alzheimer's disease. | 1991 Nov |
|
Neuroprotective activity of acetyl-L-carnitine: studies in vitro. | 1994 Jan |
|
Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. | 2002 |
|
L-acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathies. | 2006 Jul |
|
Treating Painful Diabetic Peripheral Neuropathy: An Update. | 2016 Aug 1 |
|
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). | 2018 Jun 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12455197
orally at a dosage of 2000 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7908343
The neuroprotective properties of acetyl-L-carnitine (ALCAR) were investigated in primary cell cultures from rat hippocampal formation and cerebral cortex of 17-day-old rat embryos. ALCAR (10-50 microM for 10 days) reduced the cell mortality induced by 24 hr fetal calf serum deprivation. Protection was partial when the neuronal cells, chronically treated with ALCAR (50 microM), were exposed to glutamate (0.25-1 mM) and kainic acid (250-500 microM) for 24 hr. The neurotoxicity induced by N-methyl-D-aspartate (NMDA, 250 microM) was attenuated by the acute co-exposure with ALCAR (1 mM), the chronic treatment with ALCAR (50 microM) significantly reduced the neuronal death induced by NMDA (0.25-1 mM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:39:35 GMT 2023
by
admin
on
Sat Dec 16 00:39:35 GMT 2023
|
Record UNII |
2WQN168TM5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1593400
Created by
admin on Sat Dec 16 00:39:35 GMT 2023 , Edited by admin on Sat Dec 16 00:39:35 GMT 2023
|
PRIMARY | |||
|
197763
Created by
admin on Sat Dec 16 00:39:35 GMT 2023 , Edited by admin on Sat Dec 16 00:39:35 GMT 2023
|
PRIMARY | |||
|
2504-11-2
Created by
admin on Sat Dec 16 00:39:35 GMT 2023 , Edited by admin on Sat Dec 16 00:39:35 GMT 2023
|
PRIMARY | |||
|
DTXSID60947902
Created by
admin on Sat Dec 16 00:39:35 GMT 2023 , Edited by admin on Sat Dec 16 00:39:35 GMT 2023
|
PRIMARY | |||
|
2WQN168TM5
Created by
admin on Sat Dec 16 00:39:35 GMT 2023 , Edited by admin on Sat Dec 16 00:39:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |